GlaxoSmithKline PLC
F:GS7
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
G
|
GlaxoSmithKline PLC
F:GS7
|
UK |
|
R
|
Resources Connection Inc
XMUN:RCO
|
US |
|
Atlas Salt Inc
OTC:REMRF
|
CA |
|
Life360 Inc
ASX:360
|
US |
|
G
|
GlaxoSmithKline PLC
XBER:GS7
|
UK |
|
Steel Strips Wheels Ltd
BSE:513262
|
IN |
|
Shofu Inc
F:69W
|
JP |
|
M
|
Mixi Inc
F:MXN
|
JP |
|
B
|
Bavarian Nordic A/S
F:BV3
|
DK |
|
Soleno Therapeutics Inc
F:6XC
|
US |
Wall St Price Targets
GS7 Price Targets Summary
GlaxoSmithKline PLC
According to Wall Street analysts, the average 1-year price target for GS7 is 17.57 EUR with a low forecast of 12.28 EUR and a high forecast of 24.13 EUR.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is GS7's stock price target?
Price Target
17.57
EUR
According to Wall Street analysts, the average 1-year price target for GS7 is 17.57 EUR with a low forecast of 12.28 EUR and a high forecast of 24.13 EUR.
What is the Revenue forecast for GlaxoSmithKline PLC?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Revenue has been 2%. The projected CAGR for the next 8 years is 3%.
What is the Operating Income forecast for GlaxoSmithKline PLC?
Projected CAGR
3%
Over the last 13 years, the compound annual growth rate for Operating Income has been 2%. The projected CAGR for the next 8 years is 3%.
What is the Net Income forecast for GlaxoSmithKline PLC?
Projected CAGR
4%
Over the last 13 years, the compound annual growth rate for Net Income has been 2%. The projected CAGR for the next 8 years is 4%.
